Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness

References

• Moss JL, Crosnoe LE, Kim ED, et al. Effect of rejuvenation hormones on spermatogenesis. Fertil Steril. 2013;99(7):1814–1820.
   PubMed Web of Science ®Google Scholar
• Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383–398.
   PubMed Web of Science ®Google Scholar
• Pope HG Jr., Phillips KA, Olivardia R. The adonis complex: the secret crisis of male body obsession. New York: Free Press; 2000.
   Google Scholar
• Mosley PE. Bigorexia: bodybuilding and muscle dysmorphia. Eur Eat Disord Rev. 2009;17(3):191–198.
   PubMed Web of Science ®Google Scholar
• Pope HG, Kanayama G, Athey A, et al. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371–377.
   PubMed Web of Science ®Google Scholar
• Thiblin I, Garmo H, Garle M, et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend. 2015;152:87–92.
   PubMed Web of Science ®Google Scholar
• Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation. Heart Failure. 2010;3(4):472–476.
   PubMed Web of Science ®Google Scholar
• Maravelias C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes. Toxicol Lett. 2005;158(3):167–175.
   PubMed Web of Science ®Google Scholar
• Turek PJ. Male reproductive physiology. In: Partin AW, editor. Campbell-Walsh-Wein urology. Twelfth ed. Philadelphia, PA: Elsevier, Inc. Publishing; 2021. p. 1390–1410.
   Google Scholar
• Vingren JL, Kraemer WJ, Ratamess NA, et al. Testosterone physiology in resistance exercise and training. Sports Med. 2010;40(12):1037–1053.
   PubMed Web of Science ®Google Scholar
• Walker WH. Non-classical actions of testosterone and spermatogenesis. Philos Trans R Soc B. 2010;365(1546):1557–1569.
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Gordan GS. The levator ani muscle of the rat as an index of myotrophic activity of steroidal hormones. J Pharmacol Exp Ther. 1950;99(1):38–44.
   PubMed Web of Science ®Google Scholar
• McLachlan RI, O’Donnell L, Meachem SJ, et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl. 2002;23(2):149–162.
   PubMed Web of Science ®Google Scholar
• Weinbauer GF, Nieschlag E. Gonadotrophin-releasing hormone analogue-induced manipulation of testicular function in the monkey. Hum Reprod. 1993;8(Suppl 2):45–50.
   PubMedGoogle Scholar
• Menon DK. Successful treatment of anabolic steroid–induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril. 2003;79(Suppl 3):1659–1661.
   PubMedGoogle Scholar
• Schurmeyer T, Belkien L, Knuth UA, et al. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet. 1984;323(8374):417–420.
   Google Scholar
• Turek PJ, Williams RH, Gilbaugh JHIII, et al. The reversibility of anabolic steroid-induced azoospermia. J Urol. 1995;153(5):1628–1630.
   PubMed Web of Science ®Google Scholar
• Moretti E, Collodel G, La Marca A, et al. Structural sperm and aneuploidies studies in a case of spermatogenesis recovery after the use of androgenic anabolic steroids. J Assist Reprod Genet. 2007;24(5):195–198.
   PubMed Web of Science ®Google Scholar
• Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid–induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
   PubMed Web of Science ®Google Scholar
• Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200–2205.
   PubMed Web of Science ®Google Scholar
• Kovac JR, Scovell J, Ramasamy R, et al. Men regret anabolic steroid use due to a lack of comprehension regarding the consequences on future fertility. Andrologia. 2015;47(8):872–878.
   PubMed Web of Science ®Google Scholar
• De Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860–1865.
   PubMed Web of Science ®Google Scholar
• Freeman ER, Bloom DA, McGUIRE EJ, et al. A brief history of testosterone. J Urol. 2001;165(2):371–373.
   PubMed Web of Science ®Google Scholar
• NIDA. 2020, June 9. How are anabolic steroids used? Retrieved from https://www.drugabuse.gov/publications/research-reports/steroids-other-appearance-performance-enhancing-drugs-apeds/how-are-anabolic-steroids-used on 2021 Jan 30.
   Google Scholar
• Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–651.
   PubMed Web of Science ®Google Scholar
• Cohen J, Collins R, Darkes J, et al. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. J Int Soc Sports Nutr. 2007;4(1):12.
   PubMed Web of Science ®Google Scholar
• Ip EJ, Barnett MJ, Tenerowicz MJ, et al. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757–766.
   PubMed Web of Science ®Google Scholar
• Perry HM, Wright D, Littlepage BN, et al. Dying to be big: a review of anabolic steroid use. Br J Sports Med. 1992;26(4):259–261.
   PubMedGoogle Scholar
• Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men’s use of anabolic androgenic steroids in fitness and strength training environments*. Drugs: Education, Prevention and Policy. 2017;24(3):295–305.
   Web of Science ®Google Scholar
• Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med. 1997;31(1):54–58.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC).Youth Risk Behavior Surveillance System (YRBSS) 2019: Available online at: http://www.cdc.gov/HealthyYouth/yrbs/index.htm Accessed 2021 Jan 30
   Google Scholar
• Schulenberg JE, Johnston LD, O’Malley PM, et al. (2020). Monitoring the future national survey results on drug use, 1975–2019: volume II, college students and adults ages 19–60. Ann Arbor: Institute for Social Research, The University of Michigan. [cited 2021 Jan 30]. Available from: http://monitoringthefuture.org/pubs.html#monographs.
   Google Scholar
• Kanayama G, Brower KJ, Wood RI, et al. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966–1978.
   PubMed Web of Science ®Google Scholar
• Bonnecaze AK, O’Connor T, Aloi JA, et al. Characteristics and attitudes of men using Anabolic Androgenic Steroids (AAS): a survey of 2385 men. American Journal of Men’s Health. 2020;14(6):155798832096653.
   Web of Science ®Google Scholar
• De Vries DA, Peter J, De Graaf H, et al. Adolescents’ social network site use, peer appearance-related feedback, and body dissatisfaction: testing a mediation model. J Youth Adolesc. 2016;45(1):211–224.
   PubMed Web of Science ®Google Scholar
• Mabe AG, Forney KJ, Keel PK, et al. Do you “like” my photo? Facebook use maintains eating disorder risk. Int J Eat Disord. 2014;47(5):516–523.
   PubMed Web of Science ®Google Scholar
• Griffiths S, Murray SB, Krug I, et al. The contribution of social media to body dissatisfaction, eating disorder symptoms, and anabolic steroid use among sexual minority men. Cyberpsychol Behav Social Networking. 2018;21(3):149–156.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1–7.
   PubMed Web of Science ®Google Scholar
• Shahidi N. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23(9):1355–1390.
   PubMed Web of Science ®Google Scholar
• Parssinen M, Kujala U, Vartiainen E, et al. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21(3):225–227.
   PubMed Web of Science ®Google Scholar
• Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil. 1988 August;69(8):632–633.
   PubMed Web of Science ®Google Scholar
• Mochizuki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Phys Sportsmed. 1988;16(11):109–111. 114
   PubMed Web of Science ®Google Scholar
• McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62(1):164.
   PubMed Web of Science ®Google Scholar
• Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J. 1992;124(2):507–508.
   PubMed Web of Science ®Google Scholar
• Luke JL, Farb A, Virmani R, et al. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings.J. Forensic Sci. 1990;35(6):1441–1447.
   Google Scholar
• Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death - a case report and review of the literature. Int J Legal Med. 1998;111(5):261–264.
   PubMed Web of Science ®Google Scholar
• Ahlgrim C, Guglin M. Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. J Card Fail. 2009;15(6):496–500.
   PubMed Web of Science ®Google Scholar
• Ebenbichler CF, Sturm W, Ganzer H, et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis. 2001;158(2):483–490.
   PubMed Web of Science ®Google Scholar
• Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200(2):423–432.
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettochi C, Carvalho J, et al. EAU guidelines on sexual and reproductive health 2020. In: European Association of Urology guidelines. 2020 ed. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020. vol. presented at the EAU Annual Congress Amsterdam 2020. p. 31.
   Google Scholar
• Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement. Endocr Rev. 2014;35(3):341–375.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232–240.
   PubMed Web of Science ®Google Scholar
• Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal Selective Androgen Receptor Modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597–3617.
   PubMed Web of Science ®Google Scholar
• Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Coss CC, Dalton JT, et al. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134–142.
   PubMed Web of Science ®Google Scholar
• Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004.
   PubMed Web of Science ®Google Scholar
• Naafs MA. Selective androgen receptor modulators (SARMs): a mini-review. Open Access J Reprod Sys Sex Disord. 2018;1(1):1.
   Google Scholar
• Burmeister MD, Fincher TK, Graham WH. Recreational use of selective androgen receptor modulators. US Pharm. 2020;45:15–18.
   Web of Science ®Google Scholar
• “The supreme people’s court issued the ‘interpretation on several issues concerning the application of law in the trial of criminal cases of smuggling, illegal business, and illegal doping use”. [cited 2021 Jan 30]. Available from: baijiahao.baidu.com/s?id=1650655188269513998.
   Google Scholar
• “S. 2895 (116th): sARMs Control Act of 2019.” GovTrack.us, 19 November. 2019, [cited 2021 Jan 30]. Available from: www.govtrack.us/congress/bills/116/s2895/text.
   Google Scholar
• Dressel U, Allen TL, Pippal JB, et al. The peroxisome proliferator-activated receptor β/δ Agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003;17(12):2477–2493.
   PubMedGoogle Scholar
• Mitchell JA, Bishop-Bailey D. PPAR β/δ a potential target in pulmonary hypertension blighted by cancer risk. Pulm Circ. 2019;9(1):204589401881205.
   Web of Science ®Google Scholar
• Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45–53.
   PubMed Web of Science ®Google Scholar
• Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601.
   PubMed Web of Science ®Google Scholar
• Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertil Steril. 2021;115(1):54–61.
   PubMedGoogle Scholar
• Ko EY, Siddiqi K, Brannigan RE, et al. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol. 2012;187(3):973–978.
   PubMed Web of Science ®Google Scholar
• Coviello AD, Bremner WJ, Matsumoto AM, et al. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Andrology. 2004;25(6):931–938.
   PubMed Web of Science ®Google Scholar
• Dohle GR, Smit M, Weber RFA, et al. Androgens and male fertility. World J Urol. 2003;21(5):341–345.
   PubMed Web of Science ®Google Scholar
• Feinberg MJ, Lumia AR, McGinnis MY, et al. The effect of anabolic-androgenic steroids on sexual behavior and reproductive tissues in male rats. Physiol Behav. 1997;62(1):23–30.
   PubMed Web of Science ®Google Scholar
• Grokett BH, Ahmad N, Warren DW, et al. The effects of an anabolic steroid (oxandrolone) on reproductive development in the male rat. Acta Endocrinol (Copenh). 1992;126(2):173–178.
   PubMedGoogle Scholar
• Karila T, Hovatta O, Seppala T. Concomitant abuse of anabolic androgenic steroids and human chorionic gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med. 2004;25(4):257–263.
   PubMed Web of Science ®Google Scholar
• Shokri S, Aitken RJ, Abdolvahhabi M, et al. Exercise and supraphysiological dose of nandrolone deconoate increase apoptosis in spermatogenic cells. Basic Clin Pharmacol Toxicol. 2010;106(4):324–330.
   PubMed Web of Science ®Google Scholar
• Liu PY. The present and future state of hormonal treatment for male infertility. Hum Reprod Update. 2003;9(1):9–23.
   PubMed Web of Science ®Google Scholar
• Kohn TP, Louis MR, Pickett SM, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351–357 e351.
   PubMed Web of Science ®Google Scholar
• Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. J Urol. 2021;205(1):36–43.
   PubMedGoogle Scholar
• Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Transl Androl Urol. 2018;7(S3):S348–S352.
   PubMedGoogle Scholar
• McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18(3):373–380.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Mannucci E, et al. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014;2(6):794–808.
   PubMed Web of Science ®Google Scholar
• Wenker EP, Dupree JM, Langille GM, et al. The use of hcg-based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med. 2015;12(6):1334–1337.
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429–431.
   PubMed Web of Science ®Google Scholar
• Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J. 1998;74(867):45–46.
   PubMed Web of Science ®Google Scholar
• Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595–2602.
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Pastuszak AW, Hwang K, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–650.
   PubMed Web of Science ®Google Scholar
• Kim ED, McCullough A, Kaminetsky J, et al. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–685.
   PubMed Web of Science ®Google Scholar
• Helo S, Mahon J, Ellen J, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int. 2017;119(1):171–176.
   PubMed Web of Science ®Google Scholar
• Fontenot GK, Wiehle RD, Podolski JS, et al. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice. BJU Int. 2016;117(2):344–350.
   PubMed Web of Science ®Google Scholar
• Earl JA, Kim ED, Earl JA, et al. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157–165.
   PubMed Web of Science ®Google Scholar
• Tatem AJ, Beilan J, Kovac JR, et al. Management of anabolic steroid-induced infertility: novel strategies for fertility maintenance and recovery. World J Mens Health. 2020;38(2):141–150.
   PubMedGoogle Scholar
• Ghanem H, Shaeer O, El-Segini A, et al. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril. 2010;93(7):2232–2235.
   PubMed Web of Science ®Google Scholar
• Hussein A. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Andrology. 2005;26(6):787–791.
   PubMedGoogle Scholar
• Kaminetsky J, Werner M, Fontenot G, et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628–1635.
   PubMed Web of Science ®Google Scholar
• Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720–727.
   PubMed Web of Science ®Google Scholar
• Pasqualotto FF, Fonseca GP, Pasqualotto EB et al. 2008 Azoospermia after treatment with clomiphene citrate in patients with oligospermia Fertil Steril 905 2014 e2011–2014.e
   Web of Science ®Google Scholar
• Del Giudice F, Busetto G, De Berardinis E, et al. A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. Asian J Androl. 2020;22(4):360–367.
   PubMed Web of Science ®Google Scholar
• Bates G, Begley E, Tod D, et al. A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids. J Health Psychol. 2019;24(11):1595–1612.
   PubMed Web of Science ®Google Scholar
• Bates G, Tod D, Leavey C, McVeigh J. An evidence-based socioecological framework to understand men’s use of anabolic androgenic steroids and inform interventions in this area. Drugs: Education, Prevention and Policy. 2019;26(6):484–492.
   Web of Science ®Google Scholar
• Rahnema CD, Crosnoe LE, Kim ED, et al. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology. 2015;3(2):150–155.
   PubMed Web of Science ®Google Scholar